Advertisement
Advertisement
CRDL
Cardiol Therapeutics Inc. Class A Common Shares
1.32
USDSponsored
+0.02
+1.54%
May 08, 16:00 UTC -4
Closed
Pre-Market
1.33
+0.01
+0.76%
CRDL Earnings Reports
Positive Surprise Ratio
CRDL beat 16 of 22 last estimates.
73%
Next Report
Date of Next Report
May 19, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.09
Implied change from Q4 25 (Revenue/ EPS)
--
/+28.57%
Implied change from Q1 25 (Revenue/ EPS)
--
/-10.00%
Cardiol Therapeutics Inc. Class A Common Shares earnings per share and revenue
On Apr 01, 2026, CRDL reported earnings of -0.07 USD per share (EPS) for Q4 25, beating the estimate of -0.08 USD, resulting in a 14.22% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.70% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.09 USD, with revenue projected to reach -- USD, implying an increase of 28.57% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Cardiol Therapeutics Inc. Class A Common Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Cardiol Therapeutics Inc. Class A Common Shares reported EPS of -$0.07, beating estimates by 14.22%, and revenue of $0.00, 0% as expectations.
How did the market react to Cardiol Therapeutics Inc. Class A Common Shares's Q4 2025 earnings?
The stock price moved up 3.7%, changed from $1.35 before the earnings release to $1.40 the day after.
When is Cardiol Therapeutics Inc. Class A Common Shares expected to report next?
The next earning report is scheduled for May 19, 2026.
What are the forecasts for Cardiol Therapeutics Inc. Class A Common Shares's next earnings report?
Based on 3
analysts, Cardiol Therapeutics Inc. Class A Common Shares is expected to report EPS of -$0.09 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement